BACKGROUND: Latanoprostene bunod ophthalmic solution 0.024% (LBN) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The IOP-lowering effects of LBN were demonstrated in randomized controlled trials, and the safety profile was consistent with that of topical prostaglandin analogs. The data reported here evaluated patient and/or provider satisfaction with LBN in clinical settings.

METHOD: Real-world evidence was evaluated in 2 studies: an observational study conducted in Canada and a multinational survey of eyecare providers. The observational study was a prospective, open-label, 6-week, postmarketing study that enrolled adults with elevated IOP and a diagnosis of open-angle glaucoma or ocular hypertension. Outcome measures included patient and physician satisfaction with treatment, rated independently on a scale from 0 (strongly dissatisfied) to 10 (strongly satisfied). The multinational study is a survey of licensed optometrists or ophthalmologists with at least 3 years’ experience who had prescribed LBN on-label to at least 10 patients in the previous 12 months.

RESULTS: The observational study included 59 ophthalmologists and 653 patients. At the 6-week follow-up visit, provider and patient satisfaction ratings were high: mean (SD) score of 7.8 (2.1) for physicians and 7.8 (2.3) for patients. No patients discontinued treatment during the follow-up period. Data collection in the multinational survey study is ongoing.

CONCLUSION: In a real-world patient population treated with LBN, high treatment satisfaction scores were reported by both ophthalmologists and patients. A multinational study assessing clinical practice parameters, LBN utilization patterns, and provider satisfaction is currently underway to determine the generalizability of these results.